{"id":"https://openalex.org/W4310923740","doi":"https://doi.org/10.1016/j.iotech.2022.100242","title":"130P COM701 \u00b1 nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor","display_name":"130P COM701 \u00b1 nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor","publication_year":2022,"publication_date":"2022-12-01","ids":{"openalex":"https://openalex.org/W4310923740","doi":"https://doi.org/10.1016/j.iotech.2022.100242"},"language":"en","primary_location":{"id":"doi:10.1016/j.iotech.2022.100242","doi":"https://doi.org/10.1016/j.iotech.2022.100242","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2022.100242","pdf_url":null,"source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1016/j.iotech.2022.100242","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008479799","display_name":"Ryan Joseph Sullivan","orcid":"https://orcid.org/0000-0001-5344-6645","observed_orcids":["https://orcid.org/0000-0001-5344-6645"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.J. Sullivan","raw_affiliation_strings":["Medical Oncology, MGH - Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, MGH - Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002292724","display_name":"M.R. Sharma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M.R. Sharma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045207535","display_name":"Daniel A. Vaena","orcid":"https://orcid.org/0000-0001-5389-9193","observed_orcids":["https://orcid.org/0000-0001-5389-9193"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Vaena","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126176806","display_name":"E. Hamilton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Hamilton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052100404","display_name":"Benjamin Izar","orcid":"https://orcid.org/0000-0003-2379-6702","observed_orcids":["https://orcid.org/0000-0003-2379-6702"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Izar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073348927","display_name":"D. Rasco","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Rasco","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086835807","display_name":"J.F. Gainor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Gainor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016277430","display_name":"D. Shepard","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Shepard","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008375736","display_name":"K. Papadopoulos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Papadopoulos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000519527","display_name":"E.E. Dumbrava","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E.E. Dumbrava","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081050769","display_name":"H.H. Adewoye","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H.H. Adewoye","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006952731","display_name":"Pierre J. Ferr\u00e9","orcid":"https://orcid.org/0009-0009-5125-1153","observed_orcids":["https://orcid.org/0009-0009-5125-1153"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P.J. Ferre","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006362581","display_name":"E. Ophir","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Ophir","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072347083","display_name":"M. Patel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Patel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Patnaik","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5039301683","display_name":"Bartosz Chmielowski","orcid":"https://orcid.org/0000-0002-2374-3320","observed_orcids":["https://orcid.org/0000-0002-2374-3320"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Chmielowski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3190,"currency":"USD","value_usd":3190},"apc_paid":{"value":3190,"currency":"USD","value_usd":3190},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.20239661,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":"100242","last_page":"100242"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pvrig","display_name":"PVRIG","score":0.7720000147819519},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9760000109672546},{"id":"https://openalex.org/keywords/metastatic-nsclc","display_name":"metastatic non-small cell lung cancer","score":0.9660000205039978},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9010000228881836},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8040000200271606},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6060000061988831},{"id":"https://openalex.org/keywords/heavily-pretreated-patients","display_name":"heavily pretreated patients","score":0.6230000257492065},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7509999871253967}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9174456596374512},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6278485059738159},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5486418604850769},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.48256364464759827},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.4815700054168701},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4717985987663269},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4252711832523346},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3688078820705414},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.20211926102638245},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1506551206111908},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14214813709259033}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.iotech.2022.100242","doi":"https://doi.org/10.1016/j.iotech.2022.100242","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2022.100242","pdf_url":null,"source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.iotech.2022.100242","doi":"https://doi.org/10.1016/j.iotech.2022.100242","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2022.100242","pdf_url":null,"source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4249363752","https://openalex.org/W3083632537","https://openalex.org/W4308395717","https://openalex.org/W2768300564","https://openalex.org/W3170708911","https://openalex.org/W2083455294","https://openalex.org/W2526642223","https://openalex.org/W4255443786","https://openalex.org/W2041621047","https://openalex.org/W2892190472"],"abstract_inverted_index":{"Novel":[0],"agents":[1],"are":[2],"urgently":[3],"needed":[4],"for":[5],"the":[6],"treatment":[7],"[tx]":[8],"of":[9],"patients":[10],"[pts]":[11],"with":[12,40,49],"metastatic":[13],"NSCLC":[14],"including":[15],"post":[16],"immune":[17],"checkpoint":[18],"inhibitors":[19],"(ICI).":[20],"COM701":[21,33],"[anti-PVRIG]":[22],"is":[23],"a":[24,41],"novel":[25],"1st":[26],"in":[27,47],"class":[28],"ICI.":[29],"We":[30],"hypothesized":[31],"that":[32],"\u00b1":[34],"nivolumab":[35],"will":[36],"demonstrate":[37],"antitumor":[38,59],"activity":[39],"favorable":[42],"safety":[43],"and":[44],"tolerability":[45],"profile":[46],"pts":[48],"heavily":[50],"pretreated":[51],"NSCLC.":[52],"Here,":[53],"we":[54],"present":[55],"preliminary":[56],"results":[57],"on":[58],"activity.":[60]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2022-12-21T00:00:00"}